During the past decade, LKH Innsbruck; Universitätsklinik für Dermatologie conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 3 clinical trials were completed, i.e. on average, 300% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "LKH Innsbruck; Universitätsklinik für Dermatologie" are "Basal Cell Carcinoma" (1 trials), "Malignant Melanoma" (1 trials) and "Melanoma" (1 trials). Many other conditions were trialed in "LKH Innsbruck; Universitätsklinik für Dermatologie" in a lesser frequency.

Most popular intervention types in "LKH Innsbruck; Universitätsklinik für Dermatologie" are "Drug" (3 trials). Other intervention types were less common.

The name of intervention was led by "Vemurafenib" (2 trials), "Atezolizumab" (1 trials), "Atezolizumab Placebo" (1 trials), "Cobimetinib" (1 trials) and "Placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "LKH Innsbruck; Universitätsklinik für Dermatologie" are 3 trials for "All" genders.

Currently, there are NaN active trials in "LKH Innsbruck; Universitätsklinik für Dermatologie". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in LKH Innsbruck; Universitätsklinik für Dermatologie, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in LKH Innsbruck; Universitätsklinik für Dermatologie, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".